Clinical Trial: NCT04637763
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Caribou Biosciences, Inc. |
| Information Provided By: | Caribou Biosciences, Inc. |
| Last Update Posted: | 2026-10-19 |
Study Overview
Brief Summary
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
Official Title
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Conditions
Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
Intervention / Treatment
- Genetic: CB-010
- Drug: Cyclophosphamide
- Drug: Fludarabine
Other Study ID Numbers
- CB10A
Start Date (Actual)
2021-05-26
Primary Completion Date (Actual)
2025-09-11
Study Completion Date (Estimated)
2026-12-31
Enrollment (Estimated)
72
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Caribou Biosciences, Inc. |
| Information Provided By: | Caribou Biosciences, Inc. |
| Last Update Posted: | 2026-10-19 |
Study Overview
Brief Summary
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
Official Title
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Conditions
Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
Intervention / Treatment
- Genetic: CB-010
- Drug: Cyclophosphamide
- Drug: Fludarabine
Other Study ID Numbers
- CB10A
Start Date (Actual)
2021-05-26
Primary Completion Date (Actual)
2025-09-11
Study Completion Date (Estimated)
2026-12-31
Enrollment (Estimated)
72
Study Type
Interventional
Phase
Phase 1